Body composition in premanifest Huntington's disease reveals lower bone density compared to controls

PLoS Currents

Volumn , Issue , 2011, Pages

  Goodman, Anna O G ^a   Barker, Roger A ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROCORTISONE; LEPTIN; TESTOSTERONE; VITAMIN D;

ADULT; ARTICLE; BODY COMPOSITION; BODY FAT DISTRIBUTION; BONE DENSITY; CLINICAL ARTICLE; CONTROLLED STUDY; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; HUMAN; HUNTINGTON CHOREA; HYDROCORTISONE BLOOD LEVEL; LEAN BODY WEIGHT; MALE; OSTEOLYSIS; OSTEOPENIA; TESTOSTERONE BLOOD LEVEL; VITAMIN BLOOD LEVEL; BLOOD SAMPLING; BODY IMAGE; GENDER; HUMAN TISSUE; SCORING SYSTEM;

EID: 79961128259     PISSN: None     EISSN: 21573999     Source Type: Journal    
DOI: 10.1371/currents.RRN1214     Document Type: Article

References (39)

1. Harper PS. The epidemiology of Huntington's disease. Hum Genet 1992;89:365-76.
2. Oliver JE. Huntington's chorea in Northamptonshire. Br J Psychiatry 1970;116:241-53.
3. Snell RG, MacMillan JC, Cheadle JP et al. Relationship between trinucleotide repeat expansion and phenotypic variation in Huntington's disease. Nat Genet 1993;4:393-7.
4. Gusella JF, Wexler NS, Conneally PM et al. A polymorphic DNA marker genetically linked to Huntington's disease. Nature 1983;306:234-8.
5. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. The Huntington's Disease Collaborative Research Group. Cell 1993;72:971-83.
6. Gilliam TC, Bucan M, MacDonald ME et al. A DNA segment encoding two genes very tightly linked to Huntington's disease. Science 1987;238:950-2.
7. Sharp AH, Loev SJ, Schilling G et al. Widespread expression of Huntington's disease gene (IT15) protein product. Neuron 1995;14:1065-74.
8. Li SH, Schilling G, Young WS, III et al. Huntington's disease gene (IT15) is widely expressed in human and rat tissues. Neuron 1993;11:985-93.
9. Brandt J, Folstein SE, Folstein MF. Differential cognitive impairment in Alzheimer's disease and Huntington's disease. Ann Neurol 1988;23:555-61.
10. Bamford KA, Caine ED, Kido DK, Cox C, Shoulson I. A prospective evaluation of cognitive decline in early Huntington's disease: functional and radiographic correlates. Neurology 1995;45:1867-73.
11. Shiwach R. Psychopathology in Huntington's disease patients. Acta Psychiatr Scand 1994;90:241-6.
12. Goodman AO, Murgatroyd PR, Medina-Gomez G et al. The metabolic profile of early Huntington's disease- a combined human and transgenic mouse study. Exp Neurol 2008;210:691-8.
13. Goodman AO, Rogers L, Pilsworth S et al. Asymptomatic Sleep Abnormalities Are a Common Early Feature in Patients with Huntington's Disease. Curr Neurol Neurosci Rep 2010.
14. Morton AJ, Wood NI, Hastings MH, Hurelbrink C, Barker RA, Maywood ES. Disintegration of the sleep-wake cycle and circadian timing in Huntington's disease. J Neurosci 2005;25:157-63.
15. Trejo A, Tarrats RM, Alonso ME, Boll MC, Ochoa A, Velasquez L. Assessment of the nutrition status of patients with Huntington's disease. Nutrition 2004;20:192-6.
16. Arnulf I, Nielsen J, Lohmann E et al. Rapid eye movement sleep disturbances in Huntington disease. Arch Neurol 2008;65:482-8.
17. Mangiarini L, Sathasivam K, Seller M et al. Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell 1996;87:493-506.
18. Wilkinson FL, Nguyen TM, Manilal SB et al. Localization of rabbit huntingtin using a new panel of monoclonal antibodies. Brain Res Mol Brain Res 1999;69:10-20.
19. Luthi-Carter R, Hanson SA, Strand AD et al. Dysregulation of gene expression in the R6/2 model of polyglutamine disease: parallel changes in muscle and brain. Hum Mol Genet 2002;11:1911-26.
20. Reddy PH, Charles V, Williams M, Miller G, Whetsell WO, Jr., Tagle DA. Transgenic mice expressing mutated full-length HD cDNA: a paradigm for locomotor changes and selective neuronal loss in Huntington's disease. Philos Trans R Soc Lond B Biol Sci 1999;354:1035-45.
21. Davies SW, Turmaine M, Cozens BA et al. Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation. Cell 1997;90:537-48.
22. Menalled LB, Chesselet MF. Mouse models of Huntington's disease. Trends Pharmacol Sci 2002;23:32-9.
23. Bjorkqvist M, Petersen A, Bacos K et al. Progressive alterations in the hypothalamic-pituitary-adrenal axis in the R6/2 transgenic mouse model of Huntington's disease. Hum Mol Genet 2006;15:1713-21.
24. Bjorkqvist M, Fex M, Renstrom E et al. The R6/2 transgenic mouse model of Huntington's disease develops diabetes due to deficient beta-cell mass and exocytosis. Hum Mol Genet 2005;14:565-74.
25. Sanberg PR, Fibiger HC, Mark RF. Body weight and dietary factors in Huntington's disease patients compared with matched controls. Med J Aust 1981;1:407-9.
26. Mochel F, Charles P, Seguin F et al. Early energy deficit in Huntington disease: identification of a plasma biomarker traceable during disease progression. PLoS One 2007;2:e647.
27. Stoy N, McKay E. Weight loss in Huntington's disease. Ann Neurol 2000;48:130-1.
28. Ducharme N. Male osteoporosis. Clin Geriatr Med 2010;26:301-9.
29. Markianos M, Panas M, Kalfakis N, Vassilopoulos D. Plasma testosterone in male patients with Huntington's disease: relations to severity of illness and dementia. Ann Neurol 2005;57:520-5.
30. Sai AJ, Walters RW, Fang X, Gallagher JC. Relationship between Vitamin D, Parathyroid Hormone, and Bone Health. J Clin Endocrinol Metab 2010.
31. Popovic V, Svetel M, Djurovic M et al. Circulating and cerebrospinal fluid ghrelin and leptin: potential role in altered body weight in Huntington's disease. Eur J Endocrinol 2004;151:451-5.
32. Fain JN, Del Mar NA, Meade CA, Reiner A, Goldowitz D. Abnormalities in the functioning of adipocytes from R6/2 mice that are transgenic for the Huntington's disease mutation. Hum Mol Genet 2001;10:145-52.
33. Takeda S, Elefteriou F, Levasseur R et al. Leptin regulates bone formation via the sympathetic nervous system. Cell 2002;111:305-17.
34. Ducy P, Amling M, Takeda S et al. Leptin inhibits bone formation through a hypothalamic relay: a central control of bone mass. Cell 2000;100:197-207.
35. Elefteriou F, Ahn JD, Takeda S et al. Leptin regulation of bone resorption by the sympathetic nervous system and CART. Nature 2005;434:514-20.
36. Loskutova N, Honea RA, Vidoni ED, Brooks WM, Burns JM. Bone density and brain atrophy in early Alzheimer's disease. J Alzheimers Dis 2009;18:777-85.
37. Loskutova N, Honea RA, Brooks WM, Burns JM. Reduced limbic and hypothalamic volumes correlate with bone density in early Alzheimer's disease. J Alzheimers Dis 2010;20:313-22.
38. Kremer HP, Roos RA, Dingjan G, Marani E, Bots GT. Atrophy of the hypothalamic lateral tuberal nucleus in Huntington's disease. J Neuropathol Exp Neurol 1990;49:371-82.
39. Petersen A, Gil J, Maat-Schieman ML et al. Orexin loss in Huntington's disease. Hum Mol Genet 2005;14:39-47.